330 related articles for article (PubMed ID: 36194218)
1. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.
Kaye KS; Belley A; Barth P; Lahlou O; Knechtle P; Motta P; Velicitat P
JAMA; 2022 Oct; 328(13):1304-1314. PubMed ID: 36194218
[TBL] [Abstract][Full Text] [Related]
2. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
[TBL] [Abstract][Full Text] [Related]
3. In complicated UTI or pyelonephritis, cefepime-enmetazobactam increased success vs. piperacillin-tazobactam at 14 d.
Maki DG
Ann Intern Med; 2023 Feb; 176(2):JC21. PubMed ID: 36745895
[TBL] [Abstract][Full Text] [Related]
4. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
Wagenlehner FM; Gasink LB; McGovern PC; Moeck G; McLeroth P; Dorr M; Dane A; Henkel T;
N Engl J Med; 2024 Feb; 390(7):611-622. PubMed ID: 38354140
[TBL] [Abstract][Full Text] [Related]
5. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.
Kaye KS; Rice LB; Dane AL; Stus V; Sagan O; Fedosiuk E; Das AF; Skarinsky D; Eckburg PB; Ellis-Grosse EJ
Clin Infect Dis; 2019 Nov; 69(12):2045-2056. PubMed ID: 30861061
[TBL] [Abstract][Full Text] [Related]
6. Cefepime/Enmetazobactam vs Piperacillin/Tazobactam and Complicated Urinary Tract Infection or Acute Pyelonephritis.
Hsu CK; Tsai WW; Lai CC
JAMA; 2023 Feb; 329(8):684-685. PubMed ID: 36853255
[No Abstract] [Full Text] [Related]
7. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
Wagenlehner FM; Umeh O; Steenbergen J; Yuan G; Darouiche RO
Lancet; 2015 May; 385(9981):1949-56. PubMed ID: 25931244
[TBL] [Abstract][Full Text] [Related]
8. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
9. Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial.
Qian ET; Casey JD; Wright A; Wang L; Shotwell MS; Siemann JK; Dear ML; Stollings JL; Lloyd BD; Marvi TK; Seitz KP; Nelson GE; Wright PW; Siew ED; Dennis BM; Wrenn JO; Andereck JW; Han JH; Self WH; Semler MW; Rice TW;
JAMA; 2023 Oct; 330(16):1557-1567. PubMed ID: 37837651
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Seo YB; Lee J; Kim YK; Lee SS; Lee JA; Kim HY; Uh Y; Kim HS; Song W
BMC Infect Dis; 2017 Jun; 17(1):404. PubMed ID: 28592240
[TBL] [Abstract][Full Text] [Related]
11. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA; Tambyah PA; Lye DC; Mo Y; Lee TH; Yilmaz M; Alenazi TH; Arabi Y; Falcone M; Bassetti M; Righi E; Rogers BA; Kanj S; Bhally H; Iredell J; Mendelson M; Boyles TH; Looke D; Miyakis S; Walls G; Al Khamis M; Zikri A; Crowe A; Ingram P; Daneman N; Griffin P; Athan E; Lorenc P; Baker P; Roberts L; Beatson SA; Peleg AY; Harris-Brown T; Paterson DL;
JAMA; 2018 Sep; 320(10):984-994. PubMed ID: 30208454
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
13. Cefepime/Enmetazobactam vs Piperacillin/Tazobactam and Complicated Urinary Tract Infection or Acute Pyelonephritis-Reply.
Kaye KS; Belley A; Velicitat P
JAMA; 2023 Feb; 329(8):685. PubMed ID: 36853252
[No Abstract] [Full Text] [Related]
14. A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections.
Saeed MW; Gillani SW; Mahmood RK; Vippadapu P; Hussain MW; Rathore HA
Biomed Res Int; 2022; 2022():1639114. PubMed ID: 35978637
[TBL] [Abstract][Full Text] [Related]
15. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
16. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.
Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A
J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389
[TBL] [Abstract][Full Text] [Related]
17. Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms.
McKamey L; Venugopalan V; Cherabuddi K; Borgert S; Voils S; Shah K; Klinker KP
Int J Antimicrob Agents; 2018 Nov; 52(5):719-723. PubMed ID: 30125680
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of piperacillin-tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing
Zhang W; Yan CY; Li SR; Fan TT; Cao SS; Cui B; Li MY; Fan BY; Ji B; Wang L; Cui F; Cui J; Wang L; Guan Y; Wang JW
Front Cell Infect Microbiol; 2023; 13():1093842. PubMed ID: 37207190
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes following treatment of Enterobacter species pneumonia with piperacillin/tazobactam compared to cefepime or ertapenem.
Holsen MR; Wardlow LC; Bazan JA; Fussner LA; Coe KE; Elefritz JL
Int J Antimicrob Agents; 2019 Dec; 54(6):824-828. PubMed ID: 31319191
[TBL] [Abstract][Full Text] [Related]
20.
Morrissey I; Magnet S; Hawser S; Shapiro S; Knechtle P
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
